Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis-Reference-Cited by-同舟云学术

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Published:2019-05-24 Issue:8 Volume:8 Page:3719-3728
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Hiraoka Atsushi¹^ORCID,Kumada Takashi²,Atsukawa Masanori³,Hirooka Masashi⁴,Tsuji Kunihiko⁵,Ishikawa Toru⁶,Takaguchi Koichi⁷,Kariyama Kazuya⁸,Itobayashi Ei⁹,Tajiri Kazuto¹⁰,Shimada Noritomo¹¹,Shibata Hiroshi¹²,Ochi Hironori¹³,Tada Toshifumi²,Toyoda Hidenori²^ORCID,Nouso Kazuhiro⁸,Tsutsui Akemi⁷,Nagano Takuya⁷,Itokawa Norio⁵,Hayama Korenobu⁵,Imai Michitaka⁶,Joko Kouji¹³,Koizumi Yohei⁴,Hiasa Yoichi⁴,Michitaka Kojiro¹,Kudo Masatoshi¹⁴,

Affiliation:

1. Gastroenterology Center Ehime Prefectural Central Hospital Ehime Japan

2. Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu Japan

3. Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan

4. Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan

5. Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan

6. Department of Gastroenterology Saiseikai Niigata Daini Hospital Niigata Japan

7. Department of Gastroenterology Okayama City Hospital Okayama Japan

8. Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan

9. Department of Gastroenterology Asahi General Hospital Asahi Japan

10. Department of Gastroenterology Toyama University Hospital Toyama Japan

11. Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan

12. Department of Gastroenterology Tokushima Prefectural Central Hospital Tokushima Japan

13. Hepato‐biliary Center Matsuyama Red Cross Hospital Matsuyama Japan

14. Faculty of Medicine, Department of Gastroenterology and Hepatology Kindai University Osaka Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2241

Reference32 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

3. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

4. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

5. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study;Cancer Medicine;2024-08

2. Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity;Medical Oncology;2024-02-21

3. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma;Targeted Oncology;2024-01

4. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study;Hepatology Research;2023-12-06

5. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib;2023-10-24